214 reports of this reaction
2.3% of all ZINC OXIDE reports
#9 most reported adverse reaction
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is the #9 most commonly reported adverse reaction for ZINC OXIDE, manufactured by MONAT GLOBAL CORP. There are 214 FDA adverse event reports linking ZINC OXIDE to THERAPEUTIC PRODUCT EFFECT INCOMPLETE. This represents approximately 2.3% of all 9,433 adverse event reports for this drug.
Patients taking ZINC OXIDE who experience therapeutic product effect incomplete should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE is a less commonly reported adverse event for ZINC OXIDE, but still significant enough to appear in the safety profile.
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported for ZINC OXIDE:
The following drugs have also been linked to therapeutic product effect incomplete in FDA adverse event reports:
THERAPEUTIC PRODUCT EFFECT INCOMPLETE has been reported as an adverse event in 214 FDA reports for ZINC OXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC PRODUCT EFFECT INCOMPLETE accounts for approximately 2.3% of all adverse event reports for ZINC OXIDE, making it a notable side effect.
If you experience therapeutic product effect incomplete while taking ZINC OXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.